FDA approves AstraZeneca’s Imfinzi for mismatch repair deficient primary advanced or recurrent endometrial cancer

The approval of Imfinzi is based on the Phase 3 DUO-E trial, which showed that in combination with chemotherapy, it reduced the risk of disease progression or death in mismatch repair deficient endometrial cancer by 58%.